 |
||
 |
 At Exelixis, we view rigorous clinical programs as opportunities to advance our innovative product candidates that we believe are first-in-class or best-in-class compounds while furthering the understanding and treatment of cancer. We have built a broad pipeline of highly qualified and extensively characterized compounds. We believe that each compound has meaningful clinical and commercial potential, and is designed to be a first-in-class or best-in-class therapy. The compounds currently in clinical development target pathways that play critical roles in cancer. Our development group is comprised of experienced professionals with the expertise to quickly move our development candidate compounds from preclinical testing to investigational new drug (IND) status and through phase 3 clinical trials. The development group possesses critical expertise in the areas of chemistry, manufacturing, and controls (CMC), translational medicine, pre-clinical testing, pharmacokinetics, drug safety, biostatistics, clinical trial design, management, and analysis, and regulatory affairs. The team's proficiency and productivity are remarkable assets that have enabled us to advance thirteen compounds from lead candidate to the clinic in three years. The productivity of Exelixis' discovery engine and the stringency of its screening processes will support the addition of at least three new compounds to the company's pipeline each year for the foreseeable future. Exelixis intends to leverage the quantity and quality of the compounds generated by this engine to add to our pipeline of product candidates that have the potential to significantly improve patient outcomes. |
 |
